GREER® Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) For Short Ragweed Allergies Phase III Data Published In Journal Of Allergy And Clinical Immunology
3/10/2014 8:29:27 AM
LENOIR, N.C.--(BUSINESS WIRE)--GREER®, a leading developer and provider of allergy immunotherapy products and services, announces that data from its pivotal Phase III investigational clinical trial for GREER® Sublingual (standardized short ragweed extract) Allergy Immunotherapy Liquid (SAIL)™ is published in the March issue of the Journal of Allergy and Clinical Immunology. The study marks the first successful North American Phase III clinical trial to demonstrate the safety and efficacy of a sublingual standardized ragweed allergen immunotherapy liquid extract.
Help employers find you! Check out all the jobs and post your resume.
comments powered by